Perrigo Company (NYSE:PRGO)‘s stock had its “buy” rating restated by stock analysts at Canaccord Genuity in a research note issued on Thursday, Marketbeat reports. They presently have a $88.00 target price on the stock, up from their previous target price of $80.00. Canaccord Genuity’s target price would suggest a potential upside of 13.84% from the company’s previous close.

A number of other analysts also recently commented on the stock. BidaskClub downgraded shares of Perrigo from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Cantor Fitzgerald set a $85.00 target price on shares of Perrigo and gave the stock a “buy” rating in a report on Monday, July 24th. ValuEngine downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Royal Bank Of Canada reiterated a “hold” rating and issued a $66.00 target price on shares of Perrigo in a report on Wednesday, May 24th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $71.00 target price on shares of Perrigo in a report on Wednesday, May 24th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. Perrigo currently has a consensus rating of “Hold” and a consensus target price of $85.31.

Perrigo (NYSE:PRGO) opened at 77.30 on Thursday. Perrigo has a one year low of $63.68 and a one year high of $99.14. The stock’s market capitalization is $11.08 billion. The firm has a 50-day moving average of $73.65 and a 200-day moving average of $73.10.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Thursday, August 10th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.28. Perrigo had a negative net margin of 51.04% and a positive return on equity of 11.37%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the previous year, the firm earned $1.93 EPS. Perrigo’s revenue was down 7.7% on a year-over-year basis. On average, equities research analysts forecast that Perrigo will post $4.46 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/10/perrigo-company-nyseprgo-rating-reiterated-by-canaccord-genuity.html.

Several hedge funds have recently modified their holdings of the company. UBS Asset Management Americas Inc. boosted its position in Perrigo by 2.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 339,902 shares of the company’s stock valued at $28,289,000 after buying an additional 9,617 shares during the last quarter. Teachers Advisors LLC boosted its position in Perrigo by 6.8% in the fourth quarter. Teachers Advisors LLC now owns 175,090 shares of the company’s stock valued at $14,573,000 after buying an additional 11,079 shares during the last quarter. Macquarie Group Ltd. boosted its position in Perrigo by 1.7% in the fourth quarter. Macquarie Group Ltd. now owns 103,300 shares of the company’s stock valued at $8,597,000 after buying an additional 1,685 shares during the last quarter. Chevy Chase Trust Holdings Inc. boosted its position in Perrigo by 3.2% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 123,597 shares of the company’s stock valued at $8,205,000 after buying an additional 3,792 shares during the last quarter. Finally, Bank of Montreal Can boosted its position in Perrigo by 10.8% in the first quarter. Bank of Montreal Can now owns 82,020 shares of the company’s stock valued at $5,445,000 after buying an additional 8,012 shares during the last quarter. Institutional investors and hedge funds own 76.30% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.